A multi-center, placebo-controlled, randomized, parallel group, dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk.

Trial Profile

A multi-center, placebo-controlled, randomized, parallel group, dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2012

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoplasty rejection
  • Focus Therapeutic Use
  • Acronyms LUCIDA
  • Most Recent Events

    • 31 Jul 2012 Planned number of patients changed from 175 to 350 as reported by European Clinical Trials Database record.
    • 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Sep 2007 The expected completion date for this trial is now 1 Jan 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top